{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T19:20:51Z","timestamp":1774380051236,"version":"3.50.1"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Ureaplasma colonization in preterm infants is linked to pulmonary inflammation and bronchopulmonary dysplasia (BPD). Evidence regarding the effectiveness of macrolides, including their prophylactic role in preventing BPD, remains limited. This review aimed to assess whether azithromycin reduces the incidence of BPD or death in preterm infants, with or without Ureaplasma colonization, compared with placebo or no intervention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We followed PRISMA guidelines and searched PubMed, Cochrane Library, Embase, and Google Scholar for randomized controlled trials (RCTs) evaluating azithromycin in preterm infants with unknown or confirmed Ureaplasma infection. Primary outcomes were death and BPD, while secondary outcomes included hospital stay, adverse events, and ventilation or oxygen duration. Studies not focused on preterm infants, lacking Ureaplasma status, or not randomized were excluded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A meta-analysis of six randomized controlled trials, including 1,446 preterm infants with unknown or confirmed Ureaplasma status and sample sizes ranging from 80 to 796, compared azithromycin with placebo. No significant reduction was observed in BPD incidence [risk ratio (RR)\u2009=\u20090.92, 95% CI: 0.78\u20131.09,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.35] or mortality (RR\u2009=\u20090.88, 95% CI: 0.66\u20131.18,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.39). Heterogeneity was low for mortality (\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u20090%) and moderate for BPD (\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u200961%). Secondary outcomes showed no significant differences in mechanical ventilation days (mean difference=0.07, 95% CI: \u22120.78 to 0.33,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.58), supplemental oxygen requirement (mean difference=\u22120.45, 95% CI: \u22120.98 to 0.07,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.09), or hospitalization duration (mean difference=\u22120.02, 95% CI: \u22120.19 to 0.15,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.85). Heterogeneity (\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      ) was 94% for supplemental oxygen, 71% for mechanical ventilation, and 0% for hospitalization duration. Risk-of-bias assessment identified two studies with low risk and four with unclear risk, indicating acceptable methodological quality.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This systematic review and meta-analysis evaluated azithromycin efficacy and safety in preventing BPD and reducing mortality in preterm infants. No significant reduction in BPD or mortality was observed with azithromycin compared with placebo. Secondary outcomes, including ventilation duration, supplemental oxygen use, and hospitalization length, showed no improvement. However, heterogeneity among secondary outcomes was moderate to high, and included studies were limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>PROSPERO CRD42024572847.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fped.2026.1780809","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T16:04:46Z","timestamp":1774368286000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of azithromycin in preventing bronchopulmonary dysplasia in preterm infants: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"14","author":[{"given":"Fatima","family":"Albeladi","sequence":"first","affiliation":[{"name":"College of Medicine, University of King Abdulaziz","place":["Rabigh, Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maya Essam","family":"Alhindi","sequence":"additional","affiliation":[{"name":"College of Medicine, Taif University","place":["Taif, Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raghad Essam","family":"Marghalani","sequence":"additional","affiliation":[{"name":"College of Medicine, University of King Abdulaziz","place":["Jeddah, Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tassnim Sherif","family":"Hafez","sequence":"additional","affiliation":[{"name":"College of Medicine, Almaarefa University","place":["Riyadh, Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joud Mohammed","family":"Aljuhani","sequence":"additional","affiliation":[{"name":"College of Medicine, University of King Abdulaziz","place":["Jeddah, Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arwa Mohammed Mahmud","family":"Alqadi","sequence":"additional","affiliation":[{"name":"College of Medicine, Umm Al Qura University","place":["Mecca, Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulaziz Faisal","family":"Alahmadi","sequence":"additional","affiliation":[{"name":"College of Medicine, Al-Rayyan Colleges","place":["Madinah, Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jana Muqbil","family":"Alahmadi","sequence":"additional","affiliation":[{"name":"College of Medicine, Taibah University","place":["Madinah, Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rawan Faisal","family":"Alahmed","sequence":"additional","affiliation":[{"name":"College of Medicine, King Faisal University","place":["Al-Ahsa, Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reema Mubarak","family":"Alanazi","sequence":"additional","affiliation":[{"name":"College of Medicine, Northern Border University","place":["Arar, Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riham Yousef","family":"Tashkandi","sequence":"additional","affiliation":[{"name":"College of Medicine, University of King Abdulaziz","place":["Jeddah, Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Latifa Hani","family":"AlAmiri","sequence":"additional","affiliation":[{"name":"College of Medicine, King Faisal University","place":["Al-Ahsa, Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raghad Mansour Nawar","family":"Aljuaid","sequence":"additional","affiliation":[{"name":"College of Medicine, Taif University","place":["Taif, Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Turki","family":"Alahmadi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Faculty of Medicine, King Abdulaziz University","place":["Jeddah, Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1203\/01.pdr.0000100757.38675.50","article-title":"Pulmonary Ureaplasma urealyticum is associated with the development of acute lung inflammation and chronic lung disease in preterm infants","volume":"55","author":"Kotecha","year":"2003","journal-title":"Pediatr Res"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1001\/jama.289.9.1124","article-title":"Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months","volume":"289","author":"Schmidt","year":"2003","journal-title":"JAMA"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1056\/nejmra067279","article-title":"Chronic lung disease after premature birth","volume":"357","author":"Baraldi","year":"2007","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1586\/17476348.1.2.247","article-title":"Risk factors for the development of bronchopulmonary dysplasia: the role of antenatal infection and inflammation","volume":"1","author":"Lall","year":"2007","journal-title":"Expert Rev Respir Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.siny.2009.07.013","article-title":"Chronic lung disease of prematurity: a short history","volume":"14","author":"Philip","year":"2009","journal-title":"Semin Fetal Neonatal Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e008194","DOI":"10.1136\/bmjopen-2015-008194","article-title":"Use and safety of azithromycin in neonates: a systematic review","volume":"5","author":"Smith","year":"2015","journal-title":"BMJ Open"},{"key":"B7","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1159\/000363493","article-title":"Azithromycin and other macrolides for prevention of bronchopulmonary dysplasia: a systematic review and meta-analysis","volume":"106","author":"Nair","year":"2014","journal-title":"Neonatology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/s41390-021-01437-2","article-title":"Randomized trial of azithromycin to eradicate Ureaplasma respiratory colonization in preterm infants: 2-year outcomes","volume":"91","author":"Viscardi","year":"2021","journal-title":"Pediatr Res"},{"key":"B9","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/1465-9921-8-41","article-title":"Azithromycin in the extremely low birth weight infant for the prevention of bronchopulmonary dysplasia: a pilot study","volume":"8","author":"Ballard","year":"2007","journal-title":"Respir Res"},{"key":"B10","doi-asserted-by":"publisher","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med"},{"key":"B11","first-page":"167","article-title":"What is your research question? An introduction to the PICOT format for clinicians","volume":"56","author":"Riva","year":"2012","journal-title":"J Can Chiropr Assoc"},{"key":"B12","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"B13","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"B14","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/ppul.21352","article-title":"Use of azithromycin for the prevention of bronchopulmonary dysplasia in preterm infants: a randomized, double-blind, placebo controlled trial","volume":"46","author":"Ballard","year":"2010","journal-title":"Pediatr Pulmonol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1159\/000509462","article-title":"Use of azithromycin for the prevention of lung injury in mechanically ventilated preterm neonates: a randomized controlled trial","volume":"117","author":"Nunes","year":"2020","journal-title":"Neonatology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1136\/archdischild-2019-318122","article-title":"Randomised trial of azithromycin to eradicate Ureaplasma in preterm infants","volume":"105","author":"Viscardi","year":"2020","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.3906\/sag-1107-18","article-title":"Efficacy of azithromycin for prevention of bronchopulmonary dysplasia (BPD)","volume":"42","author":"Gharehbaghi","year":"2012","journal-title":"Turk J Med Sci"},{"key":"B18","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/s2213-2600(24)00079-1","article-title":"Azithromycin therapy for prevention of chronic lung disease of prematurity (AZTEC): a multicentre, double-blind, randomised, placebo-controlled trial","volume":"12","author":"Lowe","year":"2024","journal-title":"Lancet Respir Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1002\/ppul.25230","article-title":"Azithromycin for preventing bronchopulmonary dysplasia in preterm infants: a systematic review and meta-analysis","volume":"56","author":"Razak","year":"2020","journal-title":"Pediatr Pulmonol"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1780809\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T16:04:47Z","timestamp":1774368287000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1780809\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":19,"alternative-id":["10.3389\/fped.2026.1780809"],"URL":"https:\/\/doi.org\/10.3389\/fped.2026.1780809","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]},"article-number":"1780809"}}